BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it has completed a Phase IA clinical trial in which RGN-352 was tested in 40 healthy subjects. RGN-352 is an injectable formulation of Tß4 being developed to reduce cardiac damage in patients after an acute myocardial infarction (AMI or heart attack), as well as for other potential systemic uses. The double-blind, placebo-controlled trial included four groups of ten subjects each to assess the safety of escalating doses of RGN-352 injected into the blood stream. After a 28-day follow-up of each subject and a review of all relevant data, RGN-352 was determined to be safe and well-tolerated at the four doses tested.
